Cancer cells are known to require unusually large amounts of glucose compared with non-cancerous cells [45], suggesting that high-dose, chronic CAP might be effective in downregulating GLUT expression, thereby inhibiting cancer cell metabolism. This evidence concerns the gene SLC2A1 and cancer.